Phase 3 trials of a Chinese-developed oral anti-Covid drug to be named Azvudine are now occurring in China, Russia and Brazil. Azvudine, a reverse transcriptase inhibitor, which prevents replication of the virus, has already been used for HIV. The drug has reportedly shown good antiviral activity at cellular and animal level. There is hope that medical authorities will approve the pill by December.